Analyst Ratings for WAVE Life Sciences
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on WAVE Life Sciences (NASDAQ:WVE) stock, with 4 bullish ratings and 1 indifferent rating. The average 12-month price target is $10.6, representing an 18.46% decrease from the previous average of $13.00.
June 23, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
WAVE Life Sciences (NASDAQ:WVE) received 4 bullish ratings and 1 indifferent rating from 5 analysts over the past 3 months. The average 12-month price target is $10.6, down 18.46% from the previous average.
The stock has received mostly bullish ratings from analysts, which could indicate a positive outlook for the company. However, the average 12-month price target has decreased by 18.46% from the previous average, suggesting that analysts may have lowered their expectations for the stock's performance. This mixed sentiment makes it difficult to predict the short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100